Literature DB >> 9918722

Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.

D D Leonidas1, R Shapiro, S C Allen, G V Subbarao, K Veluraja, K R Acharya.   

Abstract

Human angiogenin (Ang), an unusual member of the pancreatic RNase superfamily, is a potent inducer of angiogenesis in vivo. Its ribonucleolytic activity is weak (10(4) to 10(6)-fold lower than that of bovine RNase A), but nonetheless seems to be essential for biological function. Ang has been implicated in the establishment of a wide range of human tumours and has therefore emerged as an important target for the design of new anti-cancer compounds. We report high-resolution crystal structures for native Ang in two different forms (Pyr1 at 1.8 A and Met-1 at 2.0 A resolution) and for two active-site variants, K40Q and H13A, at 2.0 A resolution. The native structures, together with earlier mutational and biochemical data, provide a basis for understanding the unique functional properties of this molecule. The major structural features that underlie the weakness of angiogenin's RNase activity include: (i) the obstruction of the pyrimidine-binding site by Gln117; (ii) the existence of a hydrogen bond between Thr44 and Thr80 that further suppresses the effectiveness of the pyrimidine site; (iii) the absence of a counterpart for the His119-Asp121 hydrogen bond that potentiates catalysis in RNase A (the corresponding aspartate in Ang, Asp116, has been recruited to stabilise the blockage of the pyrimidine site); and (iv) the absence of any precise structural counterparts for two important purine-binding residues of RNase A. Analysis of the native structures has revealed details of the cell-binding region and nuclear localisation signal of Ang that are critical for angiogenicity. The cell-binding site differs dramatically from the corresponding regions of RNase A and two other homologues, eosinophil-derived neurotoxin and onconase, all of which lack angiogenic activity. Determination of the structures of the catalytically inactive variants K40Q and H13A has now allowed a rigorous assessment of the relationship between the ribonucleolytic and biological activities of Ang. No significant change outside the enzymatic active site was observed in K40Q, establishing that the loss of angiogenic activity for this derivative is directly attributable to disruption of the catalytic apparatus. The H13A structure shows some changes beyond the ribonucleolytic site, but sites involved in cell-binding and nuclear translocation are essentially unaffected by the amino acid replacement. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918722     DOI: 10.1006/jmbi.1998.2378

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  27 in total

1.  Structure of murine angiogenin: features of the substrate- and cell-binding regions and prospects for inhibitor-binding studies.

Authors:  Daniel E Holloway; Gayatri B Chavali; Michelle C Hares; Vasanta Subramanian; K Ravi Acharya
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-11-19

2.  A reinforced merging methodology for mapping unique peptide motifs in members of protein families.

Authors:  Hao-Teng Chang; Tun-Wen Pai; Tan-chi Fan; Bo-Han Su; Pei-Chih Wu; Chuan-Yi Tang; Chun-Tien Chang; Shi-Hwei Liu; Margaret Dah-Tsyr Chang
Journal:  BMC Bioinformatics       Date:  2006-01-25       Impact factor: 3.169

3.  Rare Angiogenin and Ribonuclease 4 variants associated with amyotrophic lateral sclerosis exhibit loss-of-function: a comprehensive in silico study.

Authors:  Aditya K Padhi; Priyam Narain; James Gomes
Journal:  Metab Brain Dis       Date:  2019-07-31       Impact factor: 3.584

Review 4.  New insights into the role of angiogenin in actin polymerization.

Authors:  Mikhail G Pyatibratov; Alla S Kostyukova
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

5.  Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography.

Authors:  D D Leonidas; G B Chavali; A M Jardine; S Li; R Shapiro; K R Acharya
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

6.  Prediction of protein deamidation rates from primary and three-dimensional structure.

Authors:  N E Robinson; A B Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

7.  A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anticodon loops.

Authors:  K Tomita; T Ogawa; T Uozumi; K Watanabe; H Masaki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

8.  A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.

Authors:  Richard Y T Kao; Jeremy L Jenkins; Karen A Olson; Marc E Key; James W Fett; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-12       Impact factor: 11.205

Review 9.  Three decades of research on angiogenin: a review and perspective.

Authors:  Jinghao Sheng; Zhengping Xu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-12-23       Impact factor: 3.848

10.  Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis.

Authors:  Sathish Sadagopan; Neelam Sharma-Walia; Mohanan Valiya Veettil; Virginie Bottero; Rita Levine; Richard J Vart; Bala Chandran
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.